natgillin/translations-raw huggingface dataset:
Kiselgelen ligger i en pose eller beholder og må ikke sluges. 
The silica gel desiccant is contained in a separate sachet or canister and should not be swallowed.
Baseret på en fase 3-populationsfarmakokinetisk analyse hos studiedeltagere med kronisk hepatitis B var det gennemsnitlige steady state-AUC0-24 for tenofoviralafenamid (N = 698) og tenofovir (N = 856) henholdsvis 0,22 µg•time/ml og 0,32 µg•time/ml. 
Based on Phase 3 population pharmacokinetic analysis in subjects with chronic hepatitis B, mean steady state AUC0-24 for tenofovir alafenamide (N = 698) and tenofovir (N = 856) were 0.22 µg•h/mL and 0.32 µg•h/mL, respectively.
Dosisjustering af midazolam (administreret oralt eller intravenøst) er ikke nødvendig. 
No dose adjustment of midazolam (administered orally or IV) is required.
d. Omfatter patienter, som seponerede lægemidlet af andre årsager end bivirkninger (AE), død eller manglende eller tab af virkning, dvs. patienter, som trak deres samtykke tilbage, patienter, der ikke kunne følges op på osv. 
d Includes patients who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy, e.g.
En minimal infiltration af histiocytter i øjet blev observeret hos hunde ved eksponeringer for tenofoviralafenamid og tenofovir, der var henholdsvis ca. 4 og 17 gange højere, end hvad der forventes efter administration af tenofoviralafenamid. 
A minimal infiltration of histiocytes was present in the eye in dogs at tenofovir alafenamide and tenofovir exposures of approximately 4 and 17 times greater, respectively, than those expected after administration of tenofovir alafenamide.
Tenofoviralafenamid hæmmer ikke human uridindifosfatglukuronosyltransferase (UGT) 1A1 in vitro. 
Tenofovir alafenamide is not an inhibitor of human uridine diphosphate glucuronosyltransferase (UGT) 1A1 in vitro.
• antimykotika, der anvendes til behandling af svampeinfektioner, og som indeholder: ketoconazol eller itraconazol. 
• antifungal medicines used to treat fungal infections, containing: ketoconazole or itraconazole
Vemlidys sikkerhed og virkning hos børn under 12 år eller med en legemsvægt < 35 kg er endnu ikke klarlagt. 
The safety and efficacy of Vemlidy in children younger than 12 years of age, or weighing < 35 kg, have not yet been established.
Tenofovir elimineres renalt, både ved glomerulær filtration og aktiv tubulær sekretion. 
Tenofovir is renally eliminated from the body by the kidneys by both glomerular filtration and active tubular secretion.
Hvis der er gået mere end 18 timer, skal patienten ikke tage den glemte dosis, men blot fortsætte med den normale doseringsplan. 
If more than 18 hours have passed from the time it is usually taken, the patient should not take the missed dose and should simply resume the normal dosing schedule.
Hos patienter, som forblev på blindet behandling efter uge 96, var den gennemsnitlige procentvise ændring i BMD i hver gruppe i uge 120 lig med den i uge 96. 
In patients who remained on blinded treatment beyond Week 96, mean percentage change in BMD in each group at Week 120 was similar to that at Week 96.
Tenofovirdiphosphat hæmmer HBV-replikation ved at blive inkorporeret i viralt DNA ved hjælp af HBV-revers transkriptase, hvilket resulterer i DNA-kædeterminering. 
Tenofovir diphosphate inhibits HBV replication through incorporation into viral DNA by the HBV reverse transcriptase, which results in DNA chain termination.
Hos patienter, som forblev på blindet behandling efter uge 96 i studie 108 og 110, var ændringen fra baseline i renale laboratorieparameterværdier hos hver gruppe i uge 120 lig med dem i uge 96. 
In patients who remained on blinded treatment beyond Week 96 in Studies 108 and 110, changes from baseline in renal laboratory parameter values in each group at Week 120 were similar to those at Week 96.
• Hvis der er gået mindre end 18 timer siden det tidspunkt, hvor du normalt tager Vemlidy, skal du tage lægemidlet snarest muligt og derefter tage den næste dosis til sædvanlig tid. 
• If it is less than 18 hours after you usually take Vemlidy, take it as soon as you can, and then take your next dose at its regular time.
Der blev ikke set nogen klinisk relevante forskelle i tenofoviralafenamids eller tenofovirs farmakokinetik mellem unge og voksne hiv 1-inficerede patienter. 
No clinically relevant differences in tenofovir alafenamide or tenofovir pharmacokinetics were observed between adolescent and adult HIV-1 infected subjects.
Der blev observeret knogletoksicitet i form af reduceret BMD hos rotter og hunde ved tenofovir-eksponeringer, der var mindst fire gange højere end dem, der forventes efter administration af tenofoviralafenamid. 
Bone toxicity was observed as reduced BMD in rats and dogs at tenofovir exposures at least four times greater than those expected after administration of tenofovir alafenamide.
Vemlidy indeholder det aktive stof tenofovir-alafenamid. 
Vemlidy contains the active substance tenofovir alafenamide.
Samtidig administration af andre lægemidler 
Co-administration with other medicinal products
• Hvis der er gået mere end 18 timer siden det tidspunkt, hvor du normalt tager Vemlidy, skal du ikke tage den glemte dosis. 
• If it is more than 18 hours after you usually take Vemlidy, then do not take the missed dose.
• Fortæl det til lægen, hvis du nogensinde har haft en leversygdom. 
• Tell your doctor if you have a history of liver disease.
Tenofoviralafenamid er et fosfonamidat-prodrug af tenofovir (2'-deoxyadenosinmonophosphatanalog). 
Tenofovir alafenamide is a phosphonamidate prodrug of tenofovir (2'-deoxyadenosine monophosphate analogue).
ORALE KONTRACEPTIVA Norgestimat (0,180 mg/0,215 mg/0,250 mg oralt, en gang dagligt) 
ORAL CONTRACEPTIVES Norgestimate (0.180 mg/0.215 mg/ 0.250 mg orally, q.d.)
Hvis du holder op med at tage Vemlidy Du må ikke holde op med at tage Vemlidy uden først at drøfte det med lægen. 
If you stop taking Vemlidy Do not stop taking Vemlidy without your doctor's advice.
Det er et lægemiddel mod virus (et antiviralt lægemiddel) og kaldes en nukleotid revers transkriptasehæmmer (NtRTI). 
This is an antiviral medicine, known as a nucleotide reverse transcriptase inhibitor (NtRTI).
Intracellulært tenofovir fosforyleres efterfølgende til den farmakologisk aktive metabolit tenofovirdiphosphat. 
Intracellular tenofovir is subsequently phosphorylated to the pharmacologically active metabolite tenofovir diphosphate.
Hos patienter med fremskreden leversygdom eller cirrose frarådes behandlingsophør, eftersom forværring af hepatitis efter behandlingsophør kan medføre hepatisk dekompensation. 
In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post-treatment exacerbation of hepatitis may lead to hepatic decompensation.
Forhøjet ALAT Hud og subkutane væv Almindelig 
Skin and subcutaneous tissue disorders Common
Hver beholder indeholder kiselgel-tørremiddel og en polyesterspiral. 
Each bottle contains silica gel desiccant and polyester coil.
Tabel 3: Parametre for virkning på HBV-DNA i uge 48a 
Table 3: HBV DNA efficacy parameters at Week 48a
Før behandling med Vemlidy iværksættes, skal alle HBV-inficerede patienter, hvis hiv 1infektionsstatus er ukendt, tilbydes test for hiv-antistoffer. 
HIV antibody testing should be offered to all HBV infected patients whose HIV-1 infection status is unknown before initiating therapy with Vemlidy.
• naturlægemider, der anvendes til behandling af depression og angst, og som indeholder: perikon (hypericum perforatum) 
• herbal remedies used to treat depression and anxiety, containing: St. John's wort (Hypericum perforatum)
Du skal ikke tage en ny tablet, hvis du kaster op mere end 1 time efter, at du har taget Vemlidy. 
You do not need to take another tablet if you are sick (vomit) more than 1 hour after taking Vemlidy.
HBV-DNA < 29 IE/ml Behandlingsforskelb 
HBV DNA < 29 IU/mL Treatment differenceb
Tenofoviralafenamid elimineres primært efter metabolisering til tenofovir. 
Tenofovir alafenamide is mainly eliminated following metabolism to tenofovir.
Tenofoviralafenamid trænger ind i primære hepatocytter ved passiv diffusion og via de hepatiske optagelsestransportører OATP1B1 og OATP1B3. 
Tenofovir alafenamide enters primary hepatocytes by passive diffusion and by the hepatic uptake transporters OATP1B1 and OATP1B3.
Vemlidy indeholder lactose 
Vemlidy contains lactose
Efter korrektion for proteinbinding er ubundne (frie) plasmakoncentrationer af tenofoviralafenamid sammenlignelige ved svært nedsat leverfunktion og normal leverfunktion. 
When corrected for protein binding, unbound (free) plasma concentrations of tenofovir alafenamide in severe hepatic impairment and normal hepatic function are similar.
Samtidig administration af Vemlidy og visse antikonvulsiva (f.eks. carbamazepin, oxcarbazepin, phenobarbital og phenytoin), antimykobakterielle lægemidler (f.eks. rifampicin, rifabutin og rifapentin) eller perikon, som alle inducerer P-glykoprotein (P-gp) og kan nedsætte plasmakoncentrationen af tenofoviralafenamid, frarådes. 
Co-administration of Vemlidy with certain anticonvulsants (e.g. carbamazepine, oxcarbazepine, phenobarbital and phenytoin), antimycobacterials (e.g. rifampicin, rifabutin and rifapentine) or St. John's wort, all of which are inducers of P-glycoprotein (P-gp) and may decrease tenofovir alafenamide plasma concentrations, is not recommended.
1 Bivirkning identificeret under sikkerhedsovervågning efter markedsføring for lægemidler indeholdende tenofoviralafenamid. 
1 Adverse reaction identified through post-marketing surveillance for tenofovir alafenamide-containing products.
Samtidig administration af sådanne lægemidler og Vemlidy frarådes. 
Co-administration of such medicinal products with Vemlidy is not recommended.
Tenofoviralafenamids antivirale aktivitet blev evalueret mod et panel med isolater indeholdende nukleosid/nukleotid revers transkriptasehæmmer-mutationer i HepG2-celler. 
The antiviral activity of tenofovir alafenamide was evaluated against a panel of isolates containing nucleos(t)ide reverse transcriptase inhibitor mutations in HepG2 cells.
Der foreligger ingen data om Vemlidys sikkerhed og virkning hos patienter, der også er inficeret med hepatitis C- eller D-virus. 
There are no data on the safety and efficacy of Vemlidy in patients co-infected with hepatitis C or D virus.
Vemlidy kan give svimmelhed. 
Vemlidy can cause dizziness.
Vemlidy er indiceret til behandling af kronisk hepatitis B hos voksne og unge (i alderen 12 år og derover med en legemsvægt på mindst 35 kg) (se pkt. 
Vemlidy is indicated for the treatment of chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg) (see section 5.1).
↔ Tenofoviralafenamid ↔ Raltegravir 
↔ Tenofovir alafenamide ↔ Raltegravir
I begge studier var tenofoviralafenamid efter 96 ugers behandling forbundet med mindre ændringer i renale sikkerhedsparametre (mindre gennemsnitsreduktioner i estimeret CrCl via Cockcroft Gaultmetoden og mindre gennemsnitlige procentvise stigninger i forholdet mellem retinolbindende protein og kreatinin i urinen og forholdet mellem beta 2-mikroglobulin og kreatinin i urinen) sammenlignet med tenofovirdisoproxilfumarat (se også pkt. 
In both studies tenofovir alafenamide was associated with smaller changes in renal safety parameters (smaller median reductions in estimated CrCl by Cockcroft-Gault and smaller median percentage increases in urine retinol binding protein to creatinine ratio and urine beta-2-microglobulin to creatinine ratio) compared to tenofovir disoproxil fumarate after 96 weeks of treatment (see also section 4.4).
Ældre Dosisjustering af Vemlidy er ikke nødvendig hos patienter på 65 år og derover (se pkt. 
Elderly No dose adjustment of Vemlidy is required in patients aged 65 years and older (see section 5.2).
Lægemidler, der inducerer P-gp (f.eks. rifampicin, rifabutin, carbamazepin, phenobarbital og perikon) forventes at nedsætte plasmakoncentrationen af tenofoviralafenamid, hvilket kan medføre tab af Vemlidys terapeutiske virkning. 
Medicinal products that are P-gp inducers (e.g., rifampicin, rifabutin, carbamazepine, phenobarbital or St. John's wort) are expected to decrease plasma concentrations of tenofovir alafenamide, which may lead to loss of therapeutic effect of Vemlidy.
• Du må ikke amme, mens du er i behandling med Vemlidy. 
• Do not breast-feed during treatment with Vemlidy.
Polyvinylalkohol (E1203) Titandioxid (E171) Macrogol (E1521) Talcum (E553b) Gul jernoxid (E172) 
Polyvinyl alcohol (E1203) Titanium dioxide (E171) Macrogol (E1521) Talc (E553b) Iron oxide yellow (E172)
Tenofoviralafenamid hydrolyseres primært til tenofovir via carboxylesterase-1 i primære hepatocytter. 
Tenofovir alafenamide is primarily hydrolysed to form tenofovir by carboxylesterase 1 in primary hepatocytes.
Hjælpestof, som behandleren skal være opmærksom på Hver tablet indeholder 95 mg lactose (som monohydrat). 
Each tablet contains 95 mg lactose (as monohydrate).
c. Behandlingsnaive patienter fik < 12 ugers oral antiviral behandling med en hvilken som helst nukleosid- eller nukleotidanalog, herunder tenofovirdisoproxilfumarat eller tenofoviralafenamid. 
c Treatment-naïve subjects received < 12 weeks of oral antiviral treatment with any nucleoside or nucleotide analogue including tenofovir disoproxil fumarate or tenofovir alafenamide.
e. Populationen anvendt til serologianalyse omfattede kun patienter med antigen (HBeAg)-positiv og antistof (HBeAb)negativ eller manglende ved baseline. 
e The population used for serology analysis included only patients with antigen (HBeAg) positive and antibody (HBeAb) negative or missing at baseline.
Normaliseret ALAT (centrallaboratorium)c Normaliseret ALAT (AASLD)d 
Normalised ALT (Central lab)c Normalised ALT (AASLD)d Serology
Isolater af HBV, der udtrykte enkeltsubstitutionerne rtA181T, rtA181V eller rtN236T associeret med resistens over for adefovir, forblev følsomme for tenofoviralafenamid, men det HBV-isolat, der udtrykte rtA181V plus rtN236T, viste nedsat følsomhed for tenofoviralafenamid (3,7 gange ændring i EC50). 
HBV isolates expressing the rtA181T, rtA181V, or rtN236T single substitutions associated with resistance to adefovir remained susceptible to tenofovir alafenamide; however, the HBV isolate expressing rtA181V plus rtN236T exhibited reduced susceptibility to tenofovir alafenamide (3.7-fold change in EC50).
Tenofoviralafenamid er substrat for OATP1B1 og OATP1B3 in vitro. 
Tenofovir alafenamide is a substrate of OATP1B1 and OATP1B3 in vitro.
• tenofovir-disoproxilfumarat 
• tenofovir disoproxil fumarate
Lactosemonohydrat Mikrokrystallinsk cellulose (E460(i)) Croscarmellosenatrium (E468) Magnesiumstearat (E470b) 
Lactose monohydrate Microcrystalline cellulose (E460(i)) Croscarmellose sodium (E468) Magnesium stearate (E470b)
Det er ukendt, om tenofoviralafenamid udskilles i human mælk. 
It is not known whether tenofovir alafenamide is secreted in human milk.
Vemlidy 25 mg filmovertrukne tabletter. 
Vemlidy 25 mg film-coated tablets.
Polyvinylalkohol (E1203), titandioxid (E171), macrogol (E1521), talcum (E553b), gul jernoxid (E172). 
Polyvinyl alcohol (E1203), titanium dioxide (E171), macrogol (E1521), talc (E553b), iron oxide yellow (E172).
Hvis patienten glemmer at tage en dosis inden for 18 timer efter det tidspunkt, hvor patienten normalt tager dosen, skal patienten tage Vemlidy så snart som muligt og derefter fortsætte med den normale doseringsplan. 
If a dose is missed and less than 18 hours have passed from the time it is usually taken, the patient should take Vemlidy as soon as possible and then resume their normal dosing schedule.
Vemlidys sikkerhed er også understøttet af samlede data fra patienter i studie 108 og 110, som forblev på blindet behandling fra uge 96 til og med uge 120 og endvidere fra patienter i den ikke-blindede fase af studie 108 og 110 fra uge 96 til og med uge 120 (N = 361 forblev på Vemlidy, N = 180 skiftede fra tenofovirdisoproxilfumarat til Vemlidy i uge 96). 
The safety of Vemlidy is also supported by pooled data from patients in Studies 108 and 110 who remained on blinded treatment from Week 96 through Week 120 and additionally from patients in the open-label phase of Studies 108 and 110 from Week 96 through Week 120 (N = 361 remained on Vemlidy; N = 180 switched from tenofovir disoproxil fumarate to Vemlidy at Week 96).
N/A = ikke relevant TDF = tenofovirdisoproxilfumarat A Manglende = fejlanalyse. 
TDF = tenofovir disoproxil fumarate a Missing = failure analysis.
På dage med hæmodialyse skal Vemlidy administreres, når hæmodialysen er fuldført (se pkt. 
On days of haemodialysis, Vemlidy should be administered after completion of haemodialysis treatment (see section 5.2).
Systemorganklasse Hyppighed Bivirkning Almindelig 
System organ class Frequency
↔ Tenofoviralafenamid ↔ Maraviroc 
↔ Tenofovir alafenamide ↔ Maraviroc
Ved baseline var middelværdien for plasma-HBV-DNA 5,8 log10 IE/ml, middelværdien for serum-ALAT var 94 E/l, og 9 % af patienterne havde cirrose i anamnesen. 
At baseline, mean plasma HBV DNA was 5.8 log10 IU/mL, mean serum ALT was 94 U/L, and 9% of patients had a history of cirrhosis.
Samtidig administration af Vemlidy og lægemidler, der hæmmer P-gp og BCRP, kan øge plasmakoncentrationen af tenofoviralafenamid. 
Co-administration of Vemlidy with medicinal products that inhibit P-gp and BCRP may increase plasma concentrations of tenofovir alafenamide.
Virkningen af tenofoviralafenamid på andre lægemidler Tenofoviralafenamid hæmmer ikke CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 eller CYP2D6 in vitro. 
Tenofovir alafenamide is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 in vitro.
Lactosemonohydrat, mikrokrystallinsk cellulose (E460(i)), croscarmellosenatrium (E468), magnesiumstearat (E470b). 
Lactose monohydrate, microcrystalline cellulose (E460(i)), croscarmellose sodium (E468), magnesium stearate (E470b).
 Fortæl det til lægen, hvis nogen af disse bivirkninger bliver alvorlige. 
 If any of these side effects get serious tell your doctor.
Ved baseline var middelværdien for plasma-HBV-DNA 7,6 log10 IE/ml, middelværdien for serum-ALAT var 120 E/l, og 7% af patienterne havde cirrose i anamnesen. 
At baseline, mean plasma HBV DNA was 7.6 log10 IU/mL, mean serum ALT was 120 U/L, and 7% of patients had a history of cirrhosis.
Isolater af HBV, der udtrykte rtL180M-, rtM204V- plus rtT184G-, rtS202G- eller rtM250V-substitutioner associeret med resistens over for entecavir, forblev følsomme for tenofoviralafenamid. 
HBV isolates expressing the rtL180M, rtM204V plus rtT184G, rtS202G, or rtM250V substitutions associated with resistance to entecavir remained susceptible to tenofovir alafenamide.
I Studie 108 blev HBeAg-negative behandlingsnaive og behandlingserfarne patienter med kompenseret leverfunktion randomiseret i forholdet 2:1 til at få Vemlidy (25 mg; N = 285) en gang dagligt eller tenofovirdisoproxilfumarat (300 mg; N = 140) en gang dagligt. 
In Study 108, HBeAg-negative treatment-naïve and treatment-experienced patients with compensated liver function were randomised in a 2:1 ratio to receive Vemlidy (25 mg; N = 285) once daily or tenofovir disoproxil fumarate (300 mg; N = 140) once daily.
I Studie 110 blev HBeAg-positive behandlingsnaive og behandlingserfarne patienter med kompenseret leverfunktion randomiseret i forholdet 2:1 til at få Vemlidy (25 mg; N = 581) en gang dagligt eller tenofovirdisoproxilfumarat (300 mg; N = 292) en gang dagligt. 
In Study 110, HBeAg-positive treatment-naïve and treatment-experienced patients with compensated liver function were randomised in a 2:1 ratio to receive Vemlidy (25 mg; N = 581) once daily or tenofovir disoproxil fumarate (300 mg; N = 292) once daily.
↔ Tenofoviralafenamid ↔ Nevirapin 
↔ Tenofovir alafenamide ↔ Nevirapine
Det bør ikke anvendes til patienter med hereditær galactoseintolerans, total lactasemangel eller glucose/galactosemalabsorption. 
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
I prøver indsamlet under kliniske studier var bindingen af tenofoviralafenamid til humane plasmaproteiner ca. 80 %. 
The binding of tenofovir alafenamide to human plasma proteins in samples collected during clinical studies was approximately 80%.
Tabel 2: Bivirkninger identificeret med tenofoviralafenamid 
Table 2: Adverse drug reactions identified with tenofovir alafenamide
Samtidig administration af Vemlidy og potente P-gp-hæmmere (f.eks. itraconazol og ketoconazol) kan øge plasmakoncentrationen af tenofoviralafenamid. 
Co-administration of Vemlidy with strong inhibitors of P-gp (e.g. itraconazole and ketoconazole) may increase tenofovir alafenamide plasma concentrations.
Behandlingsophør Behandlingsophør bør overvejes i følgende tilfælde (se pkt. 
Treatment discontinuation Treatment discontinuation may be considered as follows (see section 4.4):
Samtidig administration af potente P-gp-hæmmere og Vemlidy frarådes. 
Co-administration of strong inhibitors of P-gp with Vemlidy is not recommended.
Vemlidy-tabletter er pakket i beholdere af højdensitetspolyethylen (HDPE) med børnesikret skruelåg af popypropylen med kontinuerligt gevind, foret med induktionsaktiveret aluminiumsfolie. 
Vemlidy tablets are packaged in high density polyethylene (HDPE) bottles and enclosed with a polypropylene continuous-thread, child-resistant cap, lined with an induction-activated aluminium foil liner.
Isolater af HBV, der udtrykte rtV173L-, rtL180M- og rtM204V/I-substitutioner associeret med resistens over for lamivudin, forblev følsomme for tenofoviralafenamid (< 2 gange ændring i EC50). 
HBV isolates expressing the rtV173L, rtL180M, and rtM204V/I substitutions associated with resistance to lamivudine remained susceptible to tenofovir alafenamide (< 2-fold change in EC50).
Midazolamd (1 mg i.v., enkeltdosis) 
Midazolamd (1 mg IV, s.d.)
Det skal du vide, før du begynder at tage Vemlidy Tag ikke Vemlidy: 
What you need to know before you take Vemlidy Do not take Vemlidy
Vemlidy indeholder lactosemonohydrat. 
Vemlidy contains lactose monohydrate.
Hvis patienten kaster op mere end 1 time efter at have taget Vemlidy, skal der ikke tages ny tablet. 
If the patient vomits more than 1 hour after taking Vemlidy, the patient does not need to take another tablet.
Amning frarådes, så dit barn ikke får tenofoviralafenamid eller tenofovir gennem mælken. 
It is recommended that you do not breast-feed to avoid passing tenofovir alafenamide or tenofovir to the baby through breast milk.
Det vides ikke, om tenofoviralafenamid hæmmer andre UGT-enzymer. 
It is not known whether tenofovir alafenamide is an inhibitor of other UGT enzymes.
Opblussen efter behandlingsophør 
Flares after treatment discontinuation
Lægen afgør, hvor længe behandlingen skal fortsætte. 
Treatment should continue for as long as your doctor tells you.
NATURLÆGEMIDLER Perikon (hypericum perforatum) 
HERBAL SUPPLEMENTS St. John's wort (Hypericum perforatum)
I den ikke-blindede fase i studie 108 og 110 var den gennemsnitlige (+SD) ændring i serumkreatinin fra uge 96 til uge 120 -0,002 (0,10) mg/dl hos dem, som forblev på Vemlidy, sammenlignet med0,008 (0,09) mg/dl hos dem, som skiftede fra tenofovirdisoproxilfumarat til Vemlidy i uge 96. 
In the open-label phase of Studies 108 and 110, the mean (±SD) change in serum creatinine from Week 96 to Week 120 was -0.002 (0.10) mg/dL in those who remained on Vemlidy, compared to -0.008 (0.09) mg/dL in those who switched from tenofovir disoproxil fumarate to Vemlidy at Week 96.
Ethinylestradiol (0,025 mg oralt, en gang dagligt) 
Ethinylestradiol (0.025 mg orally, q.d.)
Giv ikke dette lægemiddel til børn under 12 år eller børn, som vejer under 35 kg. Vemlidy er ikke blevet undersøgt hos børn under 12 år eller børn, som vejer under 35 kg. 
Do not give this medicine to children who are under 12 years old or weigh less than 35 kg.
ANTIRETROVIRALE MIDLER MOD HIV - PROTEASEHÆMMERE Atazanavir/cobicistat (300 mg/150 mg oralt, en gang dagligt) 
HIV ANTIRETROVIRAL AGENTS - PROTEASE INHIBITORS Atazanavir/cobicistat (300 mg/150 mg orally, q.d.)
• Du skal beskytte dig mod graviditet, mens du er i behandling med Vemlidy. 
• Take steps to avoid getting pregnant during treatment with Vemlidy.